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Abstract
The t(12;21)(p13;q22) chromosomal translocation is themost frequent translocation in childhoodBcell precursor–acute
lymphoblastic leukemia and results in the expression of an ETV6/RUNX1 fusion protein. The frequency of ETV6/RUNX1
fusions in newborns clearly exceeds the leukemia rate revealing that additional events occur in ETV6/RUNX1–positive
cells for leukemic transformation. Hitherto, the mechanisms triggering these second hits remain largely elusive. Thus,
we generated a novel ETV6/RUNX1 transgenic mousemodel where the expression of the fusion protein is restricted to
CD19+ B cells. These animals harbor regular B cell development and lack gross abnormalities. We established stable
pro-B cell lines carrying the ETV6/RUNX1 transgene that allowed us to investigate whether ETV6/RUNX1 itself favors
the acquisition of second hits. Remarkably, these pro-B cell lines as well as primary bone marrow cells derived from
ETV6/RUNX1 transgenic animals display elevated levels of reactive oxygen species (ROS) as tested with ETV6/RUNX1
transgenic dihydroethidium staining. In line, intracellular phospho-histone H2AX flow cytometry and comet assay
revealed increased DNA damage indicating that ETV6/RUNX1 expression enhances ROS. On the basis of our data,
we propose the following model: the expression of ETV6/RUNX1 creates a preleukemic clone and leads to increased
ROS levels. These elevated ROS favor the accumulation of secondary hits by increasing genetic instability and double-
strand breaks, thus allowing preleukemic clones to develop into fully transformed leukemic cells.
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Introduction
The ETV6/RUNX1 (TEL/AML1) fusion gene is the most common
chromosomal alteration in pediatric cancer and occurs in approximately
25% of children with B cell precursor–acute lymphoblastic leukemia
(BCP-ALL) [1,2]. The t(12;21)(p13;q22) chromosomal translocation
results in the fusion of two critical regulators of hematopoiesis, bringing
together the 5′ portion of the ETV6 (TEL) gene on chromosome
12p13 and nearly the entire RUNX1 (AML1) gene on chromosome
21q22 [3,4]. Persuasive evidence that clearly shows the presence of
the ETV6/RUNX1 fusion already prenatally and defines it as an early
and initiating mutation is available. These insights were obtained
from studies of identical twins with concordant ALL [5] and retrospec-
tive screening of archived neonatal blood spots of children diagnosed
with ALL [6]. The early arise of the translocation indicates that it pre-
sents the first event (“hit”) in the process of leukemogenesis creating a
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preleukemic clone. This is further supported by the fact that the
fusion gene may be present for up to 10 years before leukemia diag-
nosis [7,8]. Secondary genetic events are clearly required for the
clinical manifestation of the leukemia that evolves from an ETV6/
RUNX1+ preleukemic clone that is characterized by the surface markers
CD34+CD38−/lowCD19+ [9,10].
At the time point of diagnosis, ETV6/RUNX1+ ALL is charac-
terized by multiple copy number alterations [11,12]. So far, it is elusive
how the presence of ETV6/RUNX1 induces the acquisition of these
additional genetic events during pathogenesis of BCP-ALL.
Genomic instability is one of the characteristics of transformed cells
[13] and may arise from increased DNA damage and/or impaired
DNA repair [14]. DNA damage occurs due to spontaneous decay
but also results from exposure to radiation or certain chemicals. Re-
active oxygen species (ROS) are chemically reactive molecules that
participate in self-propagating reactions, and, if allowed to accumulate,
they can cause oxidative damage to intracellular macromolecules,
including DNA, proteins, and lipids [15]. The increased mutation rate
in a variety of cancers has been attributed to the accumulation of
ROS [16]. The capability of ROS to induce DNA double-strand
breaks (DSBs) stresses the potential of ROS for triggering chromosomal
aberrations [17–20]. Additionally to ROS-mediated mutagenesis,
the expression of leukemia-associated fusion genes may interfere with
DNA repair as convincingly demonstrated for breakpoint cluster region/
Abelson 1 (BCR/ABL1) leukemia [21]. DNA repair is also disturbed in
leukemic cells characterized by translocation products such as RUNX1/
ETO (AML1/ETO) [22,23] and in cases of ETV6/RUNX1+ leukemia
[12]. ETV6/RUNX1+ cells also display a disrupted spindle checkpoint
that may result in aneuploidy [24].
In this study, we describe a novel mouse model where ETV6/
RUNX1 expression is restricted to CD19+ B lymphoid cells. In line
with earlier reports [25–30], we did not observe leukemia formation in
these animals. Here, we describe for the first time that the expression
of ETV6/RUNX1 is associated with increased levels of ROS and the
subsequent accumulation of DSBs, a prerequisite for mutagenesis.
These findings suggest that the expression of ETV6/RUNX1 triggers
mutagenesis through enhanced ROS production.
Design and Methods
Generation of a CD19+ B Cell–Specific
ETV6/RUNX1-Expressing Mouse
To generate a mouse that expresses ETV6/RUNX1 specifically
in CD19+ cells, the CD19 bacterial artificial chromosome (BAC)
RP23-407K24 was used. For BAC modification, the building vec-
tor pQS-CD19 containing an EcoRI and NheI restriction site was
used [31]. The human ETV6/RUNX1 cDNA was amplified from
an pMSCV-ETV6/RUNX1–internal ribosomal entry site (IRES)–
green fluorescent protein (GFP) plasmid (a kind gift of O. Williams,
University College London, Institute of Child Health, London,
United Kingdom) using the primers 5′ GCGGAATTCATGT-
CTGAGACTCCTGCTCAG 3′ containing an EcoRI site and
5′ GCGGCTAGCTTAAGCGTAATCTGGAACATCGTATG-
GGTA 3′ containing an NheI site and a hemagglutinin (HA)
tag. This fragment was inserted into the plasmid pQS-CD19
using EcoRI and NheI restriction sites. After NotI digestion, the
linearized form of pQS-CD19-ETV6/RUNX1 was used to insert
the ETV6/RUNX1-IRES-hCD2t expression cassette into the
mouse CD19 BAC RP23-407K24 by standard BAC modifica-
tion procedures as described earlier [32]. The expression cassette
was thereby inserted into exon 1 of the CD19 BAC to express
ETV6/RUNX1 and hCD2t under the control of the Cd19 pro-
motor. Upon recombination, the start codon (ATG) of the Cd19
coding sequence in exon 1 is replaced by the ETV6/RUNX1-IRES-
hCD2t-polyA expression cassette. Transcription from the Cd19 pro-
moter is terminated by a polyadenylation signal just after the hCD2t
coding sequence. Furthermore, the inserted bicistronic cDNA is not
in frame with the Cd19 coding sequence. Transgenic mice were gen-
erated by injection of linearized BAC DNA at 1 ng/μl into pronuclei
of C57BL/6×CBA F1 zygotes. The transgenic animals were backcrossed
to C57BL/6 mice for seven generations. ETV6/RUNX1 transgenic
(E/Rtg) mice were genotyped using the following oligos: forward—
5′GCCAGACATTGTGGCATATG3′ and reverse—5′CGAGTCT-
TCCTCCATCCTGA 3′. Mice were kept at the animal facility at
Research Institute of Molecular Pathology/Institute of Molecular
Biotechnology (IMP/IMBA; Vienna, Austria). All animal experiments
were carried out in accordance with protocols approved by the animal
committee of the Medical University of Vienna and by the Federal
Ministry of Science and Research.
Southern Blot Analysis
Twenty micrograms of tail genomic DNA of wt and E/Rtg litter-
mates were digested with BamHI, separated on a 1% agarose gel, trans-
ferred to a nylon membrane (Macherey-Nagel, Düren, Germany), and
hybridized with a probe downstream of the insertion site of the ETV6/
RUNX1-IRES-hCD2t expression cassette (amplification primers,
forward—5′ GGTATCGAGGTAACCAGTCAACACCC 3′ and
reverse—5′ GTACCCCACAGGACAGCCAAAGTGTGG 3′).
mRNA Expression Analysis and Semiquantitative Reverse
Transcription–Polymerase Chain Reaction Analysis
Total RNA from bone marrow (BM) and spleen was isolated using
TRIzol (TRI Reagent; Sigma-Aldrich, Vienna, Austria) and sub-
sequently treated with DNase I (DNase I recombinant; Roche Diag-
nostics, Vienna, Austria). cDNA was prepared with RevertAid H
Minus First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot,
Germany) using random hexamer primers. Sequences of primer pairs
used during the course of the study (5′-3′) are given as follows:
ETV6/RUNX1, forward—CTCTGTCTCCCCGCCTGAA and
reverse—CGGCTCGTGCTGGCAT; mouse Etv6, forward—
GATAGTGGATCCCAACGGACT and reverse—ACGTTTGTTC-
ATCCAGCACTT; and mouseHprt, forward—GATACAGGCCAG-
ACTTTGTTG and reverse—GGTAGGCTGGCCTATAGGCT.
Blood Smears and Blood Parameters
Blood smears were stained with Hemacolor Rapid staining of blood
smear staining set (Merck Millipore, Billerica, MA). Confocal images
(original magnification, ×100) were taken using aCarl Zeiss (Oberkochen,
Germany) Axio Imager.Z1 microscope. Blood parameters were mea-
sured from EDTA blood by scil Vet ABC (Gurnee, IL) according to
the manufacturers’ instructions.
Flow Cytometric Analysis
Single-cell suspensions were preincubated with anti-CD16/CD32
(24G2) antibody to prevent nonspecific Fc receptor–mediated
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binding. Antibodies used for lineage determination included CD3e
(145-2C11), Ter119 (Ter119), Gr-1 (RB6-8C5), CD11b (M1/70),
and CD19 (1D3). An antibody against human CD2 (RPA 2.1; all
BD Biosciences, San Jose, CA) as marker for ETV6/RUNX1 expres-
sion was used. Staining for free oxygen radicals was performed
using dihydroethidium (DHE; Molecular Probes, Eugene, OR). For
flow cytometric detection of phospho-histone H2AX (γH2AX; S139;
Cell Signaling Technology; clone 20E3), B cells were fixed in
paraformaldehyde (Sigma-Aldrich; 2%), permeabilized by exposure to
ice-cold methanol (−20°C, 30 minutes), washed in phosphate-buffered
saline containing 0.5% BSA (Sigma-Aldrich) and 0.2% Tween 20
(Sigma-Aldrich), and stained with an Alexa Fluor 647–conjugated
γH2AX antibody (Cell Signaling Technology, Danvers, MA)
for 60 minutes (room temperature). Subsequently, cells were washed
and analyzed. Samples were acquired on a BD FACSCanto II FACS
device (BD Biosciences), and data were analyzed with FlowJo software
(TreeStar, Ashland, OR).
Protein Analysis
Protein expression has been determined from the fetal liver–
derived CD19+ B cell lines of wt and E/Rtg mice. Cells were lysed in
a buffer containing protease and phosphatase inhibitors [25 mMHepes
(pH 7.5), 150 mM NaCl, 10 mM EDTA, 0.1% Tween 20, 0.5%
NP-40, 10 mM β-glycerophosphate, 40 μl/ml protease inhibitor
cocktail (Roche, Basel, Switzerland), 0.1 mM PMSF, 0.1 mMNaVO4,
and 1 mM DTT]. The protein concentration was determined by Bio-
Rad protein assay kit as recommended by the manufacturer (Bio-Rad
Laboratories, Hercules, CA). ETV6/RUNX1 was immunoprecipitated
of 2 mg of cell lysate using an anti-RUNX1 antibody (N-20;
Santa Cruz Biotechnology, Dallas, TX) and probed with a polyclonal
Figure 1. Design of BAC and expression analysis of the ETV6/RUNX1 transgene. (A) The ETV6/RUNX1-IRES-hCD2t expression cassette
was inserted in the first exon of the Cd19 gene. (B) Southern blot analysis of the Cd19 locus in an ETV6/RUNX1 founder mouse. Genomic
DNA was digested with BamHI, blotted on a nitrocellulose membrane, and hybridized with a radiolabeled DNA probe against the proxi-
mal region of the Cd19 intron 1. The expected insertion of the ETV6/RUNX1-IRES-hCD2t-polyA cassette gives rise to a labeled DNA frag-
ment of 5169 bp in contrast to the wt Cd19 allele (6840 bp). (C) The reporter hCD2t is specifically expressed in CD19+ cells. BM cells
of wt mice (upper panel) and E/R-expressing mice (lower panel) were isolated, stained for surface markers CD11b, Gr1, CD3e, Ter119
as well as CD19, and analyzed by flow cytometry. The reporter gene hCD2t is only expressed in CD19+ cells but not in other hematopoietic
lineages. Black inlet shows percentage of hCD2t+ cells from the CD19-expressing population. (D) Distribution of the hCD2t expression
levels on the entire CD19+ cell fraction. One representative histogram of hCD2thigh/low-expressing CD19+ cells is shown.
(E) mRNA expression analysis for ETV6/RUNX1 and Etv6 in semiquantitative reverse transcription–PCR in FACS-sorted hCD2tlow/high cells
of the BM and the spleen of wt and E/Rtg mice. The wedge shows five-fold dilution series. (F) ETV6/RUNX1 protein expression was analyzed
by immunoprecipitation (anti-RUNX1) andWestern blot analysis (anti-ETV6) from E/Rtg andwt fetal liver–derived B cell lines. As control, 293T
cells transiently transfected with an E/R-expressing plasmid were used. An unspecific antibody cross-hybridization signal is visible in some
of the samples (wt).
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antiserum directed against ETV6 [directed against helix-loop-helix
(HLH) domain, a kind gift of Jan Cools, Center for Human Genetics,
Faculty of Medicine, KU Leuven (University of Leuven; Leuven,
Belgium)]. Proteins were electrophoretically resolved on an 8% poly-
acrylamide gel containing sodium dodecyl sulfate and transferred onto
a polyvinylidene difluoride membrane (Whatman, Piscataway, NJ).
Sites of antibody binding were detected using protein A–conjugated
HRP (GE Healthcare, Little Chalfont, United Kingdom) with
enhanced chemiluminiscence detection (GE Healthcare).
Infection of Fetal Livers and Cell Culture
Fetal liver cells of embryos (E14.5) were prepared, and single-cell
suspensions were infected as previously described [33]. After outgrowth
of cell lines, the cells were tested by flow cytometry for CD19 and
hCD2t expression.
Transformed fetal liver and BM cells were maintained in RPMI
(Sigma-Aldrich) containing 10% heat-inactivated fetal calf serum (PAA
Laboratories, Pasching, Austria), 100 U/ml penicillin/streptomycin
(Life Technologies, Carlsbad, CA), and 5 μM β-mercaptoethanol
(Sigma-Aldrich). A010 cells that produce an ecotropic replication-
deficient form of the Abelson virus were maintained in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich) supplemented with 10% heat-
inactivated fetal calf serum (PAA Laboratories), 100 U/ml L-glutamine
(Life Technologies), and 100 U/ml penicillin/streptomycin (Life Tech-
nologies). Viral supernatant was prepared as previously described [33].
Comet Assay
DNA damage was detected using the CometAssay or single gel
electrophoresis assay following the manufacturer’s protocol (Trevigen,
Gaithersburg, MD). Briefly, 106 cells/ml medium of freshly isolated
BM cells [enriched for CD19+ B cells by magnetic activated cell sorting
(MACS)] were mixed 1:10 (v.v−1) with low melting point agar at 38°C
and immediately pipetted onto agar-covered slides. Slides were incu-
bated at 4°C in the dark for 30 minutes, and the coverglass was
removed, immersed in chilled lysis solution, and incubated again at
4°C for 60 minutes. Slides were placed in a horizontal electrophoresis
chamber and electrophoresed with buffer (0.3 N NaOH and 1 mM
EDTA) at 0.3 A for 20 minutes. Samples were dried and stained with
CometAssay Silver Staining Kit (Trevigen). Comet tails were imaged
using a model BA310 microscope (Motic, Hongkong) and quantified
by TriTek CometScore (TriTek Corp, Sumerduck, VA). A minimum
of 50 cells were scored per sample.
Statistics
All statistical analyses were done using GraphPad Prism 4 (SanDiego,
CA). Differences were assessed for statistical significance by unpaired
Student’s t test and one-way analysis of variance using the Tukey
Multiple Comparison Test if not otherwise mentioned. Error bars
represent means ± SD. P values are considered as follows: <.05: *,
<.01: **, and <.001: ***.
Results
Generation of a CD19-Specific ETV6/RUNX1 Mouse
ETV6/RUNX1+ BCP-ALL is characterized by the expansion of
B cells expressing the D-related antigens Cd19 and CD10 (equivalent
to Hardy Fraction C) [34]. To express the ETV6/RUNX1 fusion
Figure 2. Effects of ETV6/RUNX1 expression on blood physiology and B cell development. (A) Representative blood smears of 8-week-old
wt and E/Rtg mice. (B) Blood parameters of wt (n= 7) and E/Rtg (n= 8)mice asmeasured by scil Vet ABC. Statistical analysis using unpaired
t test revealed no differences. (C) Flow cytometric analysis of B cell development. Shown are representative dot plots. Different develop-
mental B cell stages are indicated in the quadrants of the dot plots as pre, early, and late and pre, immature, and mature. (D) Statistical
analysis of B cell development of wt and E/Rtg mice using Student’s unpaired t test. A summary of three experiments is shown.
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protein in CD19+ B cells, a BAC containing the Cd19 locus was
modified through homologous recombination in Escherichia coli
[31,32]. A cassette encoding the human fusion gene ETV6/RUNX1
linked through an IRES to a truncated human CD2 (hCD2t) antigen
reporter and followed by a polyadenylation signal (polyA) was inserted
into the first exon of the Cd19 gene. As a result of the recombination
strategy, expression of functional Cd19 from the BAC is prevented
(Figure 1A). Several transgenic lines were obtained from oocyte injec-
tion of the CD19-ETV6/RUNX1 BAC. Southern blot analysis
revealed that line 1, which was further analyzed in detail and used
in the present study, harbors four copies of the CD19-ETV6/RUNX1
BAC (Figure 1B). To determine specific expression of ETV6/RUNX1
in B cells, we analyzed hCD2t reporter gene expression in various
hematopoietic cell lineages isolated from BM by flow cytometry.
hCD2t reporter expression was restricted to CD19+ cells and could
not be detected in any other cell type analyzed (Figure 1C ). CD19+
cell–specific expression of ETV6/RUNX1mRNA was further confirmed
by performing real-time PCR analysis (FigureW1). The uniform expres-
sion of the hCD2t reporter gene within the CD19+ cell population
(Figure 1D) indicated that essentially all ETV6/RUNX1 transgene
CD19+ cells express the ETV6/RUNX1 fusion protein. Consistently,
using semiquantitative reverse transcription–polymerase chain reaction
(PCR), we detected the ETV6/RUNX1 transgene expression both in
hCD2thigh and hCD2tlow populations (Figure 1E).
As the fusion gene is expressed under the control of the ETV6 pro-
moter in patients with leukemia, we also tested whether the expression
levels of the ETV6/RUNX1 transgene and the endogenous Etv6 gene
are within the same range. As depicted in Figure 1E , ETV6/RUNX1
and Etv6 genes were expressed at comparable levels in CD19+hCD2tlow
cells indicating that the transgene is expressed at a nearly physiological
level. Finally, we confirmed ETV6/RUNX1 expression at protein level
in CD19+ B cells (Figure 1F ).
Unaltered Hematopoiesis in E/Rtg Mice
ETV6/RUNX1tg (E/Rtg) mice are born at normal mendelian ratio
and do not display any gross abnormalities (FigureW2).We next tested
whether the expression of ETV6/RUNX1 in the CD19+ B lymphoid
compartment impacts on hematopoiesis in general and on B cell
development in particular. Various hematopoietic lineages of wt and
E/Rtg mice were assessed by flow cytometry. No consistent differences
Figure 3. E/R expression induces ROS production in vitro and in vivo. (A and B) Fetal liver cells of wt and E/Rtg mice were infected with
a retrovirus encoding for p160v-ABL. Stably transformed pro-B cell lines were analyzed for the expression of the surface markers (A) CD19
and hCD2t as well as (B) CD19 and B220. (C) wt and E/Rtg cell lines were stained with DHE and subsequently analyzed by flow cytometry
to measure differences in ROS level. One representative histogram is depicted. (D) A summary of all experiments using wt and E/Rtg cell
lines stained with DHE is shown. Statistical analysis was carried out by one-tailed paired t test (P = .04). (E) wt and E/Rtg cell lines were
treated for 24 hours with 5 mM ROS scavenger NAC and analyzed for ROS by flow cytometry. Depicted are histograms for wt (left panel)
and E/Rtg (right panel) untreated cells and cells treated with NAC. (F) CD19+ BM cells of E/Rtg (n = 16) and control littermate mice (n = 10)
were analyzed for ROS levels. Bar graphs represent DHE-MFI ± SD; statistical differences were revealed using unpaired t test. (G) Indicated
human and murine cell lines were transfected with a retrovirus encoding for E/R-IRES-GFP or GFP. The fold difference in DHE-MFI of
GFP-positive versus GFP-negative cells is shown. (H) Bar graphs depict average fold change in DHE-MFI on E/R or GFP expression ± SD
of all five cell lines analyzed. *P < .05 (unpaired t test).
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were detected between the transgenic and control mice (Figure W3,
A and B). Similarly, we failed to detect any alterations in various
blood parameters that may indicate an altered blood physiology as
assessed by blood smears and a hematocytometer. Briefly, no differ-
ences in hematocrit levels, white blood cell counts, platelet numbers,
or hemoglobin levels were detected (Figure 2, A and B). ETV6/
RUNX1+ ALL cells are arrested at the pro-B cell stage [26,27]. To
analyze B cell development in our CD19-specific E/Rtg mice, we
stained BM and splenocytes for B cell surface markers corresponding
to distinct developmental stages (Figure 2C ). Gating of the early B cell
fractions according to Hardy in the BM revealed no significant differ-
ences in pre–pro-B cells, early pro-B cells, and late pro-B cells, respec-
tively, between wt and E/Rtg mice (Figure 2D, left panel ). Interestingly,
we observed slightly increased pre-B cell and immature B cell num-
bers in the spleen of E/Rtg animals although mature B cells were com-
parable; however, this did not meet the criteria of statistical significance
(Figure 2D, right panel).
ETV6/RUNX1 Elevates Cellular ROS Levels
Oncogenes such as BCR/ABL1 induce the production of ROS
[17]. To investigate whether ETV6/RUNX1 affects the equilibrium
of ROS production and scavenging, we generated stable pro-B cell lines
from transgenic and control mice. This allowed us to address the
impact of ETV6/RUNX1 on DNA damage in vitro in a stable and
reproducible setting. Fetal liver cells from wt and E/Rtg littermate
embryos were infected with the Abelson virus that immortalizes
pro-B cells in vitro [35,36]. ETV6/RUNX1 transgene expression was
confirmed by surface-marker staining of the reporter gene hCD2t
(Figure 3A), followed by flow cytometric analysis. No changes in the
expression of the pro-B cell surface markers CD19+B220+CD43+ and
the proliferation rate of the cell lines were detected upon expression of
ETV6/RUNX1 when analyzed by flow cytometry and when assessed
by growth curves, respectively (Figures 3B and W4).
Remarkably, the analysis of ROS levels in the E/Rtg pro-B cells
consistently revealed about a two-fold increased mean fluorescence
intensity (MFI) for the ROS-sensitive fluorescence probe DHE com-
pared to control cells (wt DHE-MFI = 5700 vs E/Rtg DHE-MFI =
12,100; Figure 3, C and D). To verify that indeed an elevated ROS
level accounts for the detected differences in DHE values, we treated
our cells with the ROS scavenger N-acetyl-cystein (NAC) for 24 hours
before measurement. A clear reduction in ROS levels was detected
in E/Rtg as well as control cell lines (40% and 35% reduction in
DHE-MFI, respectively; Figure 3E ). To exclude the possibility of
an Abelson oncogene–related impact on our experimental setup, we
analyzed ex vivo–derived BM cells from our E/Rtg mice. CD19+ BM
cells of E/Rtg mice (n = 16) displayed significantly elevated DHE
fluorescence compared to littermate controls (n = 10; DHE-MFI =
1690 ± 138 and 1298 ± 31, respectively; P = .0365; Figure 3F ), indi-
cating that the observed differences are associated with ETV6/RUNX1
expression. Further evidence came from another experiment where we
used five cell lines derived from different tissues of both murine and
human origin (NIH3T3, HEPA1-6, RAW, MBA, and 32D). These
cells were infected with a retrovirus encoding for ETV6/RUNX1-
IRES-GFP or GFP alone. All cell lines tested except NIH3T3 reacted
with an increase of ROS on ETV6/RUNX1 expression (P = .0285;
Figure 3, G and H).
Accumulation of DNA DSBs on ETV6/RUNX1 Expression
It is a common feature of oncogenes to enhance DNA mutation rate
[37]. The increased mutation rate may result from both an enhanced
DNA damage and/or deregulated DNA repair mechanisms. Upon
DNA DSBs, serine residue 139 of histone H2AX (γH2AX) becomes
phosphorylated. This may be used as a sensitive marker to detect the
presence of DSBs [38,39]. When we stained wt and E/Rtg cell lines
with a γH2AX-specific antibody and analyzed them through intra-
cellular flow cytometry, we found higher levels of DSBs in ETV6/
RUNX1+ cells compared to control cells (γH2AX MFI = 3069 and
2012, respectively; Figure 4A). To assess DSBs in ex vivo–derived
BM cells of wt and E/Rtg mice, we employed a comet assay. In such
an assay, cells are embedded in agarose on microscope slides, lysed, and
subjected to electrophoresis at high pH resulting in comet-like struc-
tures of theDNA. BM-derived and BM-sorted B cells were used directly
ex vivo in this comet assay, which resulted in a higher percentage of
comet tail DNA, an indicator of DNA damage, for E/Rtg-derived B cells
compared to wt counterparts (43.3% vs 30.6%; Figure 4, B and C ).
These results suggested a link between E/Rtg expression and DSBs, a
prerequisite for DNA mutations.
Discussion
The ETV6/RUNX1 fusion gene has been described to arise already
in utero [5,9,40], producing a preleukemic clone that may progress
to full-blown leukemia when acquiring additional genetic altera-
tions [5,9,11]. Here, we report the generation of a mouse model for
Figure 4. E/R expression induces DNA damage in wt and E/Rtg cells. (A) wt and E/Rtg cell lines were stained for γH2AX and analyzed by
flow cytometry. One representative histogram is shown. (B and C) Comet assay of MACS-enriched CD19+ B cells derived from BM of wt
and E/Rtg mice. Two mice of each genotype were pooled before MACS. (B) Representative pictures of comets of each genotype.
(C) Statistical analysis (unpaired t test) of comet assay of wt and E/Rtg mice (n = 6 each) is depicted. Fifty pictures per sample were
taken for statistical analysis of percentage of tail DNA. Average ± SD of each sample is shown.
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ETV6/RUNX1 where transgene expression is driven by a BAC
containing the CD19-regulatory expression elements, restricting its
expression to the B lymphoid lineage. We describe that ETV6/
RUNX1-expressing B lymphoid cells display increased levels of ROS
accompanied by increased DNA DSBs. Thus, we propose a model
where ETV6/RUNX1 induces DNA instability through ROS de-
regulation, thereby facilitating mutagenesis and the appearance of
additional genetic alterations.
Several reports described that enforced expression of the ETV6/
RUNX1 fusion gene from retroviral promoters impairs B cell develop-
ment and induces a block at the pro-B cell stage [26], leading to the
expansion of the CD19+ B cell fraction [41]. Interestingly, we failed
to detect any changes in B cell development at the pro-B cell stage.
However, we observed a trend in elevated numbers of immature B cells
as well as pre-B cells in the spleen of E/Rtg mice. Several reasons
may account for these differences. Importantly, we succeeded in ob-
taining ETV6/RUNX1 expression at similar levels when compared to
the endogenous Etv6 gene. Thus, it is attractive to speculate that higher
ETV6/RUNX1 levels are required to inflict a B cell differentiation
block. In addition, one may reason that the onset of transgenic ex-
pression accounts for the different impact on B cell development; it
may be of relevance at which stage of B cell development the transgene
is expressed. In our case, transgene expression is under the control of
the Cd19 promoter and thereby restricted to already committed B cells.
In contrast, other studies employed promoters that allowed for ETV6/
RUNX1 expression already at earlier developmental stages such as in
hematopoietic stem and/or progenitor cells. This may support the
concept that the expression of ETV6/RUNX1 before B lymphoid
development is required.
ETV6/RUNX1 is commonly assumed to be the first hit during
leukemogenesis, and it is assumed that secondary alterations have
to occur for the clinical manifestation of the disease. In line, animal
models for ETV6/RUNX1 in mice and zebra fish revealed that the
expression of the fusion gene does not suffice to allow for leukemo-
genesis [25–30]. Van der Weyden et al. used random mutagenesis
using a Sleeping Beauty transposon to induce BCP-ALL in ETV6/
RUNX1 knock-in mice [42]. Several cooperating mutations were
identified in these mice, some of which resembled alterations in
BCP-ALL cases (including regulators of B cell development). Although
a few mutations prevail, genome-wide profiling of genetic alterations in
ETV6/RUNX1+ BCP-ALL revealed that the mutational spectrum is
highly heterogeneous, with numerous recurrent lesions generating
mutations or copy number alterations in only a few patients [11,43].
Although the animal model for ETV6/RUNX1+ leukemia that Van
der Weyden et al. used in their study relied on the usage of knock-in
mice [42], a few reports also suggest that the human ETV6/RUNX1
gene fusion—as used for the generation of our transgenic animals—
could lead to leukemia development if combined with a secondary
hit in mice. It has been reported either for BM transplantation experi-
ments where the human gene fusion was combined with loss of
p16/p19 [25] or also in a recent study on inducible E/R transgenic
mice in combination with loss of p16 [44] that the human fusion
gene was able to induce leukemogenesis in mice.
Intracellular redox homeostasis is maintained by balancing ROS
production with ROS scavenging through cellular antioxidant defense
systems [45]. Several pathophysiological conditions including leukemia
[46] have been associated with unbalanced ROS metabolism. More-
over, ROS is known to oxidize DNA that further provokes mutation
of genes that may promote carcinogenesis [47]. In this report, we show
for the first time that ETV6/RUNX1 expression in B cells is associated
with elevated endogenous ROS levels and an increase in DSBs (Fig-
ures 3 and 4). The finding that a chromosomal translocation product
induces DNA damage through ROS production is not entirely sur-
prising as it has already been shown to be true for other chromosomal
alterations and oncogenes; ample evidence supports this concept {sum-
marized in [48]}. The expression of RUNX1/ETO or RUNX1 itself
in human fibroblasts suffices to elevated intracellular ROS levels when
compared to empty vector control [49]. These data have been sup-
ported in a Drosophila model where the expression of RUNX1/ETO
resulted in high levels of ROS [50]. In our hands, the expression of
the ETV6/RUNX1 fusion product in B cells, but also various other
cell types, increased ROS levels in the respective cells. This observation
also suggests that increased ROS production induced by RUNX1-
containing translocation products could be a common mechanism
driving leukemogenesis.
ROS is viewed as an important signaling mediator [51] and may
be implicated in gene-regulatory pathways such as the one involving
hypoxia-inducible factor 1 (HIF-1) [52,53]. Interestingly, ETV6/
RUNX1 was shown to downregulate expression of DNA damage-
inducible transcript 4 (DDIT4) (also known as REDD1), an important
HIF-1 effector [54], whereas the loss of DDIT4 was reported to induce
HIF-1 stabilization and tumorigenesis through a ROS-dependent
mechanism [55], suggesting a possible link between ETV6/RUNX1
and increased ROS accumulation in patients.
Irradiation and topoisomerase II inhibitors are therapeutic modal-
ities that induce DSBs [56]. This predicts that cells harboring ETV6/
RUNX1 ought to be more sensitive to topoisomerase inhibitors.
In fact, this prediction has been verified with patient-derived cells;
BCP-ALL cells are highly sensitive to doxorubicine and etoposide,
if they are ETV6/RUNX1+. However, these cells do not differ from
ETV6/RUNX1− BCP-ALL cells with respect to their susceptibility to
other therapeutically relevant agents (vincristine, glucocorticoids,
cytarabine, alkylating agents, and thioguanin) [57]. Taken together,
our data propose a novel mechanism of how additional mutations
could be acquired in an ETV6/RUNX1+ preleukemic clone that then
could cause leukemia development.
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Figure W1. ETV6/RUNX1 is specifically expressed in CD19+ B cells
of E/Rtg mice. BM and spleen of wt and E/Rtg mice (n= 3 each) were
analyzed for ETV6/RUNX1 mRNA expression by real-time
PCR. Depicted are means ± SD. The SYBR green method was used
for quantification of the PCR product. Sequences of primer pairs
used were given as follows (5′-3′): ETV6/RUNX1, forward—
CTCTGTCTCCCCGCCTGAA and reverse—CGGCTCGTGCTGGCAT;
mouse gapdh, forward—5′-AGAAGGTGGTGAAGCAGGCATC-3′ and
reverse—5′-CGGCATCGAAGGTGGAAGAGTG-3′.
Figure W2. The expression of ETV6/RUNX1 in the CD19+B lymphoid
compartment does not lead to gross abnormalities in hematopoietic/
lymphatic organs. Representative examples of hematoxylin and eosin
(H&E)-stained sections of spleen (top panel), liver (second panel),
lung (third panel), and bone (fourth panel) of wt and E/Rtg mice are
depicted. Spleens, livers, lungs, and bone were fixed with 4% para-
formaldehyde for 24 hours, dehydrated, and embedded in paraffin.
After fixation, theboneswereadditionally decalcified inEDTA.Sections
(5 Am) were stained with H&E using standard protocols. Images
were taken using a Carl Zeiss Axio Imager.Z1 microscope.
Figure W3. The expression of ETV6/RUNX1 in the CD19+ B lymphoid compartment does not affect hematopoietic lineages other than
the B cell lineage. (A) BM of wt and E/Rtg mice was analyzed for myeloid, T-lymphoid, and erythroid lineage markers by flow cytometry.
Representative dot plot diagrams are depicted. (B) Bar graphs depict statistical analysis of hematopoietic lineages of wt and E/Rtg mice.
Percentages of Gr-1/CD11b+, CD3e+, and Ter119+ cells in whole BM are shown. No consistent differences were detected between the
transgenic and control mice as analyzed by unpaired t test.
Figure W4. E/R transgenic cells proliferate with similar kinetics as
wt controls. An amount of 106 cells of the E/Rtg and wt cell lines,
respectively, was plated, and total cell numbers were determined
after indicated days. The increase in cell number is shown in the
graph. The experiment was performed more than three times. A
summary of the experiment is depicted. Data points show means
of 12 or 6 (as indicated), and whiskers represent SE. We did not
observe significant differences in growth between the cell lines as
analyzed by unpaired t test for each time point.
